Screener
Ionis Pharmaceuticals IONS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Effects of exchange rates on cash | (188) | 827 |
| Net increase (decrease) in cash and cash equivalents | (22,195) | 55,227 |
| Cash and cash equivalents at beginning of period | 372,260 | 242,077 |
| Cash and cash equivalents at end of period | $$350,065 | 297,304 |
| Supplemental disclosures of cash flow information: | ||
| Interest paid | $$5,212 | 5,214 |
| Income taxes paid (refunds received), net | $$1,200 | (383) |
| Supplemental disclosures of non-cash investing and financing activities: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's cash & equivalents?
- Ionis Pharmaceuticals (IONS) reported cash & equivalents of $350.07M in Q2 2026.
- How has Ionis Pharmaceuticals's cash & equivalents changed year-over-year?
- Ionis Pharmaceuticals's cash & equivalents increased by 17.7% year-over-year, from $297.3M to $350.07M.
- What is the long-term trend for Ionis Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's cash & equivalents has grown at a -1.3% compound annual growth rate (CAGR), from $397.66M to $372.26M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Ionis Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude